The TAILOR-PCI Trial evaluates the outcomes between genotype-guided P2Y12 inhibitor selection versus conventional prescribing on ischemic outcomes. Listen to Geoff Wall and guest, Jake Galdo, discuss the role of pharmacogenomics in patient care.
This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!
See omnystudio.com/listener for privacy information.